Peptides News and Research

RSS

Scientists determine structure of staph, anthrax enzyme

Researchers at the U.S. Department of Energy's Argonne National Laboratory and the University of Chicago have determined the crystal structure of sortase B, an enzyme found in the bacteria that cause staph and anthrax. While an antibiotic is probably five to seven years away, the structure could provide the first clue in developing a treatment for the infections.

15 Jul 2004

Targeted therapeutics capable of preventing or limiting the metastasis of skin cancer

An international team of scientists has identified an important molecular link involved in the spread – or metastasis – of melanoma to other organs such as the lungs.

15 Jul 2004

Research that directs cancer-killing immune cells against the deadliest brain tumors shows promise

Researchers seeking to direct cancer-killing immune cells against the deadliest brain tumors have three new targets that show promise in laboratory studies and in a Phase I patient trial, according to two articles in the July 15 issue of the journal Cancer Research.

15 Jul 2004

New research offers clues into how the body controls appetite and food intake

Concurrent with the national obesity epidemic has been a rise in the discoveries about how the body controls appetite and food intake.

30 Jun 2004

Delphi expands medical footprint

Delphi Medical Systems Corporation, a subsidiary of Delphi Corporation, recently signed a licensing agreement with Switzerland-based medical device company Debiotech, S.A.

29 Jun 2004

Treating cocaine addiction with a virus

Scientists at The Scripps Research Institute have designed a potentially valuable tool for treating cocaine addiction by creating a modified "phage" virus that soaks up the drug inside the brain.

24 Jun 2004

New patent for screening technology

MorphoSys AG announced today that the U.S. Patent & Trademark Office has granted a new patent on its proprietary CysDisplay™ screening technology.

24 Jun 2004

Research on the potential oral delivery of a current intravenous cancer drug using polymeric nano-delivery systems technology

Labopharm Inc. today announced that it has entered into an agreement with Debiopharm S.A. under which Debiopharm has engaged Labopharm to conduct research on the potential oral delivery of a current intravenous cancer drug using Labopharm’s proprietary polymeric nano-delivery systems technology (also referred to as micelles technology).

16 Jun 2004

Project aimed at eliminating anthrax as a potential weapon for terrorists

La Trobe University scientists are using their own unique peptide 'library' containing a thousand million molecular sequences in a project aimed at eliminating anthrax as a potential weapon for terrorists.

10 Jun 2004

Australian scientists have developed a tool that acts as a pregnancy test for the detection of anthrax

Once a deadly disease associated with animals, anthrax is now used as a bioterrorist weapon. While infection can be controlled with antibiotics, in a bioterrorism attack people will not know they have been infected until symptoms develop, at which stage drugs are useless.

7 Jun 2004

BioSante publishes oral insulin study

BioSante Pharmaceuticals, Inc. has announced the publication of positive results of a preclinical study of its proprietary calcium phosphate nanoparticle (CAP) delivery system for the oral delivery of insulin in the June 11 issue of the peer-reviewed International Journal of Pharmaceutics.

2 Jun 2004

Double-punch approach to vaccine design more effective

A study revealing new information about how viral proteins move between cells and alert the immune system suggests that a double-punch approach to vaccine design would make them more effective.

1 Jun 2004

Blueprint for rational design of vaccines that induce desired T-cell responses

Investigators from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have conducted studies in mice to gain a new picture of how the immune system’s “killer” T cells are prompted to destroy infected cells. Their insights provide a blueprint for rational design of vaccines that induce desired T-cell responses.

27 May 2004

Research may lead to elimination of surface-induced thrombus formation

A University of Missouri-Rolla researcher’s investigation into how proteins adhere to surfaces may lead the elimination of surface-induced thrombus formation, a phenomenon known to cause blood clots in artificial arteries, valves and veins.

26 May 2004

New company is developing advanced therapeutics for stroke victims

Arizona Engineered Therapeutics Inc., a new company based on the research of three Arizona State University professors, is moving its first drug candidate closer to clinical trials.

26 May 2004

Zengen announces positive results of treatment for vaginal yeast infection

Zengen Inc. announced today positive phase I/II results for its proprietary molecule CZEN-002 for the treatment of vulvovaginal candidiasis (VVC), commonly known as vaginal yeast infection.

25 May 2004

Data suggests potential target for Alzheimer's disease treatment

Researchers from Weill Cornell Medical College and Columbia University College of Physicians & Surgeons have discovered at least one way in which beta-amyloid, the protein that forms stubborn plaques in the brains of Alzheimer's disease patients, can kill nerve cells.

25 May 2004

Researchers have isolated a protein receptor in chickens responsible for transferring antibodies from mother to offspring

Howard Hughes Medical Institute (HHMI) researchers have isolated a protein receptor in chickens that is responsible for transferring antibodies from mother to offspring - a function critical to bestowing a temporary immunity that protects the young against infection until their own immune systems begin functioning.

24 May 2004

Risk of artery plaques increased by use of HIV drugs

An Italian study has provided evidence that HIV drugs called protease inhibitors may increase the risk of artery "plaques."

15 May 2004

Viragen and University of Miami to advance anti-cancer study

Viragen, Inc. today announced that the Company extended its agreement with the University of Miami and UM/Sylvester Comprehensive Cancer Center to develop a novel form of an immune enhancing drug (IEP 11) that has shown promise in animal studies by inhibiting tumor growth in a broad range of cancers.

12 May 2004